scholarly journals The Brighton Collaboration case definition: Comparison in a retrospective and prospective cohort of children with Guillain‐Barré syndrome

2020 ◽  
Vol 25 (4) ◽  
pp. 344-349
Author(s):  
Rudolf Korinthenberg ◽  
James J. Sejvar
Keyword(s):  
Prospective Cohort ◽  
Case Definition ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Guillain-Barre Syndrome following Primary Cytomegalovirus Infection: A Prospective Cohort Study

2011 ◽  
Vol 52 (7) ◽  
pp. 837-844 ◽  
Author(s):  
D. Orlikowski ◽  
R. Porcher ◽  
V. Sivadon-Tardy ◽  
J.-C. Quincampoix ◽  
J.-C. Raphael ◽  
...  
Keyword(s):  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Cytomegalovirus Infection ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Primary Cytomegalovirus Infection ◽  
Guillain Barré

Incidence of Guillain‐Barré Syndrome in an Uruguayan population. A Prospective Cohort Study

2021 ◽  
Author(s):  
Mercedes Chiesa ◽  
Rodrigo Decima ◽  
Andrés Bertinat ◽  
Luciana Poggi ◽  
Heber Hackembruch ◽  
...  
Keyword(s):  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Active pharmacovigilance of the seasonal trivalent influenza vaccine produced by Instituto Butantan: A prospective cohort study of five target groups

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0246540
Author(s):  
Tazio Vanni ◽  
Beatriz da Costa Thomé ◽  
Mayra Martho Moura de Oliveira ◽  
Vera Lúcia Gattás ◽  
Maria da Graça Salomão ◽  
...  
Keyword(s):  
Adverse Events ◽  
Pregnant Women ◽  
Prospective Cohort ◽  
Healthcare Workers ◽  
Vaccine Safety ◽  
Median Number ◽  
Influenza Vaccines ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Introduction Active pharmacovigilance studies are pivotal to better characterize vaccine safety. Methods These are multicenter prospective cohort studies to evaluate the safety of the 2017 and 2018 seasonal trivalent influenza vaccines (TIVs) manufactured by Instituto Butantan, by means of active pharmacovigilance practices. Elderly, children, healthcare workers, pregnant women, and women in the puerperium period were invited to participate in the study during the 2017 and 2018 Brazilian national seasonal influenza vaccination campaigns. Following immunization, participants were observed for 30 minutes and they received a participant card to register adverse events information. All safety information registered were checked at a clinical site visit 14 days after immunization and by a telephone contact 42 days after immunization for unsolicited Adverse Events (AE) and Guillain-Barré Syndrome (GBS). Results A total of 942 volunteers participated in the two studies: 305 elderly, 109 children, 108 pregnant women, 32 women in the postpartum period, and 388 health workers. Overall, the median number of AR per participant ranged from 1 to 4. The lowest median number of AR per participant was observed among healthcare workers (1 AR per participant) and the highest among pregnant women (4 AR per participant). Overall, local pain (46.6%) was the most frequent solicited local AR. The most frequent systemic ARs were: headache (22.5%) followed by fatigue (16.0%), and malaise (11.0%). The majority of solicited ARs (96%) were mild, Grades 1 or 2), only 3% were Grade 3, and 1% was Grade 4. No serious AEs, including Guillain-Barré Syndrome, were reported up to 42 days postvaccination. Conclusion The results from the two studies confirmed that the 2017 and 2018 seasonal trivalent influenza vaccines produced by Instituto Butantan were safe and that active pharmacovigilance studies should be considered, when it is feasible, as an important initiative to monitor vaccine safety in the post-marketing period.

Sign in / Sign up

Export Citation Format

Share Document